LYON, France, April 9, 2008 (PRIME NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today a research cooperation with Epitarget AS, a Norwegian Company, and INSERM, to work at improving delivery of cancer drugs using a combination of ultrasound sensitive liposomes and therapeutic ultrasound (HIFU). Entitled, "Novel Sonosensitive Liposomes and Systems for Targeted Ultrasound Mediated Drug Delivery," the project has recently been awarded a public grant via the French Norwegian Foundation funded by the Foundation, the French Ministry of Research and the French Innovation Society. The project has also obtained EUREKA status, which is a European quality label and prerequisite for obtaining French public support on industrial projects.
